{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:06:43Z","timestamp":1787166403930,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T00:00:00Z","timestamp":1525651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for treatment of hyperuricemia and gout. This phase 1b, multiple\u2010dose, drug\u2010drug interaction study evaluated the pharmacokinetics, pharmacodynamics, and tolerability of verinurad in combination with allopurinol. Adult males with gout were randomized to receive once\u2010daily oral doses of allopurinol 300\u00a0mg or verinurad 10\u00a0mg alone for 7\u00a0days, allopurinol 300\u00a0mg\u00a0+\u00a0verinurad 10\u00a0mg on days 8 to 14, and the alternative single agent on days 15 to 21. Colchicine 0.6\u00a0mg was taken prophylactically for gout flares. Plasma\/serum and urine samples were assayed for verinurad, allopurinol, oxypurinol (allopurinol active metabolite), colchicine (plasma only), and uric acid. Safety was assessed by adverse events (AEs) and laboratory tests. Verinurad plasma exposure was unaffected by allopurinol. Verinurad increased the maximum observed plasma concentration (C\n                    <jats:sub>max<\/jats:sub>\n                    ) for allopurinol by 33%; the area under the plasma concentration\u2010time curve (AUC) was unaffected. Oxypurinol C\n                    <jats:sub>max<\/jats:sub>\n                    and AUC were reduced 32% and 38%, respectively, by verinurad. Colchicine plasma exposure was unaltered by verinurad. The maximum decrease in serum urate was greater with verinurad\u00a0+\u00a0allopurinol (65%) than with verinurad (51%) or allopurinol (43%) alone. Compared with the baseline rate, the maximum rate of uric acid excreted in urine was +56% with verinurad, \u221246% with allopurinol, and unchanged with verinurad\u00a0+\u00a0allopurinol. No serious AEs, discontinuations due to AEs, or clinically significant laboratory abnormalities were noted. Despite decreased systemic exposure of allopurinol and oxypurinol in the presence of verinurad, the combination resulted in greater serum urate reduction compared with either drug alone and was well tolerated at the studied doses.\n                  <\/jats:p>","DOI":"10.1002\/jcph.1119","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T11:48:47Z","timestamp":1525693727000},"page":"1214-1222","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout"],"prefix":"10.1002","volume":"58","author":[{"given":"Martin","family":"Kankam","sequence":"first","affiliation":[{"name":"Vince &amp; Associates Clinical Research, Inc Overland Park KS USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Hall","sequence":"additional","affiliation":[{"name":"Former employee of Ardea Biosciences, Inc San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gillen","sequence":"additional","affiliation":[{"name":"AstraZeneca Gaithersburg MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Former employee of Ardea Biosciences, Inc San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zancong","family":"Shen","sequence":"additional","affiliation":[{"name":"Former employee of Ardea Biosciences, Inc San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lee","sequence":"additional","affiliation":[{"name":"Former employee of Ardea Biosciences, Inc San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Liu","sequence":"additional","affiliation":[{"name":"Former employee of Ardea Biosciences, Inc San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Miner","sequence":"additional","affiliation":[{"name":"Former employee of Ardea Biosciences, Inc San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Walker","sequence":"additional","affiliation":[{"name":"Former employee of Ardea Biosciences, Inc San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Clauson","sequence":"additional","affiliation":[{"name":"Former employee of Ardea Biosciences, Inc San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wilson","sequence":"additional","affiliation":[{"name":"Former employee of Ardea Biosciences, Inc San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Former employee of Ardea Biosciences, Inc San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0175-z"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.32"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201687"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0624-3"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.05.005"},{"key":"e_1_2_9_9_1","unstructured":"AstraZeneca. Zurampic (lesinurad).2016.http:\/\/www.azpicentral.com\/zurampic\/zurampic.pdf#page=1. Accessed January 6 2017."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.144"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI42344"},{"key":"e_1_2_9_12_1","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: a phase III clinical trial","author":"Dalbeth N","journal-title":"Arthritis Rheumatol."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202594"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10511"},{"issue":"2","key":"e_1_2_9_15_1","first-page":"ii9","article-title":"Treating to target: a strategy to cure gout","volume":"48","author":"Perez\u2010Ruiz F","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1239193"},{"key":"e_1_2_9_17_1","volume-title":"Gout: Diagnosis and Management of Gouty Arthritis and Hyperuricemia","author":"Terkeltaub R","year":"2013"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00706-7"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S140658"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101156"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.9.545"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"e_1_2_9_23_1","unstructured":"Guidance for Industry.Bioanalytical Method Validation. US Department of Heath and Human Services Food and Drug Administration.2001.http:\/\/www.fda.gov\/downloads\/Drugs\/Guidance\/ucm070107.pdf. Accessed June 28 2017."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.1.89"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00870986"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1124\/dmd.105.006056","article-title":"Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone","volume":"33","author":"Iwanaga T","year":"2005","journal-title":"Drug Metab Dispos."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315283"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207919"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2016.04.007"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.1119","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:49:44Z","timestamp":1751604584000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,7]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1002\/jcph.1119"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1119","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,7]]},"assertion":[{"value":"2017-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}